Fig_ID,Article_ID,figure,dep_variable,control_name,treated_name,OBS,Results
242,80,Fig 2(second graph),cell viability (%),0uM (Aβ),1uM (Aβ),,214
243,80,Fig 2(second graph),cell viability (%),0uM (Aβ),2uM (Aβ),,215
244,80,Fig 2(second graph),cell viability (%),0uM (Aβ),4uM (Aβ),,216
245,80,Fig 2(second graph),cell viability (%),0uM (Aβ),8uM (Aβ),,217
246,80,Fig 2(second graph),cell viability (%),0uM (Aβ),12uM (Aβ),,218
247,80,Fig 2(second graph),cell viability (%),0uM (Aβ),16uM (Aβ),,219
248,80,Fig 2(second graph),cell viability (%),0uM (Aβ),24uM (Aβ),,220
249,81,Fig 1,cell viability (%),0uM (Aβ),1.5uM (Aβ),,221
250,81,Fig 1,cell viability (%),0uM (Aβ),10uM (Aβ),,222
251,81,Fig 1,cell viability (%),0uM (Aβ),12.5uM (Aβ),,223
252,81,Fig 1,cell viability (%),0uM (Aβ),15uM (Aβ),,224
253,81,Fig 1,cell viability (%),0uM (Aβ),20uM (Aβ),,225
254,82,Fig 3,cell viability (%),0uM (Aβ),2.5uM (Aβ),,226
255,83,Fig 5a,cell viability (%),0uM (Aβ),0.5uM (Aβ),,227
256,83,Fig 5a,cell viability (%),0uM (Aβ),1uM (Aβ),,228
257,83,Fig 5a,cell viability (%),0uM (Aβ),5uM (Aβ),,229
258,83,Fig 5a,cell viability (%),0uM (Aβ),10uM (Aβ),,230
259,83,Fig 5a,cell viability (%),0uM (Aβ),20uM (Aβ),,231
260,83,Fig 5c,cell viability (%),0uM (Aβ),10uM (Aβ),,232
261,84,Fig 3d,cell viability (%),0uM (Aβ),0.1uM (Aβ),,233
262,84,Fig 3d,cell viability (%),0uM (Aβ),0.25uM (Aβ),,234
263,84,Fig 3d,cell viability (%),0uM (Aβ),0.5uM (Aβ),,235
264,84,Fig 3d,cell viability (%),0uM (Aβ),1uM (Aβ),,236
265,84,Fig 3d,cell viability (%),0uM (Aβ),2.5uM (Aβ),,237
266,84,Fig 3d,cell viability (%),0uM (Aβ),5uM (Aβ),,238
267,84,Fig 3d,cell viability (%),0uM (Aβ),10uM (Aβ),,239
268,85,Fig 2a,MTT reduction (% vs untreated cells),untreated cells,0.5h 1uM (Aβ1-42) D,differentiated,240
269,85,Fig 2a,MTT reduction (% vs untreated cells),untreated cells,3h 1uM (Aβ1-42) D,differentiated,241
270,85,Fig 2a,MTT reduction (% vs untreated cells),untreated cells,6h 1uM (Aβ1-42) D,differentiated,242
271,85,Fig 2a,MTT reduction (% vs untreated cells),untreated cells,24h 1uM (Aβ1-42) D,differentiated,243
272,85,Fig 2a,MTT reduction (% vs untreated cells),untreated cells,0.5h 1uM (Aβ1-42) UD,undifferentiated,244
273,85,Fig 2a,MTT reduction (% vs untreated cells),untreated cells,3h 1uM (Aβ1-42) UD,undifferentiated,245
274,85,Fig 2a,MTT reduction (% vs untreated cells),untreated cells,6h 1uM (Aβ1-42) UD,undifferentiated,246
275,85,Fig 2a,MTT reduction (% vs untreated cells),untreated cells,24h 1uM (Aβ1-42) UD,undifferentiated,247
276,85,"Fig 2b
",MTT reduction (% vs untreated cells),untreated cells,0.01uM (Aβ1-42) D,differentiated,248
277,85,"Fig 2b
",MTT reduction (% vs untreated cells),untreated cells,0.1uM (Aβ1-42) D,differentiated,249
278,85,"Fig 2b
",MTT reduction (% vs untreated cells),untreated cells,1uM (Aβ1-42) D,differentiated,250
279,85,"Fig 2b
",MTT reduction (% vs untreated cells),untreated cells,10uM (Aβ1-42) D,differentiated,251
280,85,"Fig 2b
",MTT reduction (% vs untreated cells),untreated cells,0.01uM (Aβ1-42) UD,undifferentiated,252
281,85,"Fig 2b
",MTT reduction (% vs untreated cells),untreated cells,0.1uM (Aβ1-42) UD,undifferentiated,253
282,85,"Fig 2b
",MTT reduction (% vs untreated cells),untreated cells,1uM (Aβ1-42) UD,undifferentiated,254
283,85,"Fig 2b
",MTT reduction (% vs untreated cells),untreated cells,10uM (Aβ1-42) UD,undifferentiated,255
284,85,"Fig 3b
",MTT reduction (% vs untreated cells),untreated cells,1uM (Aβ1-42) D,differentiated,256
285,85,"Fig 3b
",MTT reduction (% vs untreated cells),untreated cells,1uM (Aβ1-42) UD,undifferentiated,257
286,85,"Fig 3b
",MTT reduction (% vs untreated cells),untreated cells,1uM (Aβ1-40) D,differentiated,258
287,85,"Fig 3b
",MTT reduction (% vs untreated cells),untreated cells,1uM (Aβ1-40) UD,undifferentiated,259
288,86,Fig 7a,MTT reduction (% vs untreated cells),untreated cells,3.125uM (Aβ1-40),"fresh
",260
289,86,Fig 7a,MTT reduction (% vs untreated cells),untreated cells,6.25uM (Aβ1-40),"fresh
",261
290,86,Fig 7a,MTT reduction (% vs untreated cells),untreated cells,12.5uM (Aβ1-40),"fresh
",262
291,86,Fig 7a,MTT reduction (% vs untreated cells),untreated cells,25uM (Aβ1-40),"fresh
",263
292,86,"Fig 7b
",MTT reduction (% vs untreated cells),untreated cells,3.125uM (Aβ1-40),aged,264
293,86,"Fig 7b
",MTT reduction (% vs untreated cells),untreated cells,6.25uM (Aβ1-40),aged,265
294,86,"Fig 7b
",MTT reduction (% vs untreated cells),untreated cells,12.5uM (Aβ1-40),aged,266
295,86,"Fig 7b
",MTT reduction (% vs untreated cells),untreated cells,25uM (Aβ1-40),aged,267
296,86,Fig 7c,MTT reduction (% vs untreated cells),untreated cells,0.3125uM (Aβ1-42),aged,268
297,86,Fig 7c,MTT reduction (% vs untreated cells),untreated cells,3.125uM (Aβ1-42),aged,269
298,86,Fig 7c,MTT reduction (% vs untreated cells),untreated cells,6.25uM (Aβ1-42),aged,270
299,86,Fig 7c,MTT reduction (% vs untreated cells),untreated cells,12.5uM (Aβ1-42),aged,271
300,86,Fig 7c,MTT reduction (% vs untreated cells),untreated cells,25uM (Aβ1-42),aged,272
301,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,0.231uM (Aβ1-40),fresh,273
302,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,2.31uM (Aβ1-40),fresh,274
303,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,11.55uM (Aβ1-40),fresh,275
304,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,23.1uM (Aβ1-40),fresh,276
305,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,0.231uM (Aβ1-40),aged,277
306,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,2.31uM (Aβ1-40),aged,278
307,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,11.55uM (Aβ1-40),aged,279
308,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,23.1uM (Aβ1-40),aged,280
309,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,0.231uM (Aβ1-42),fresh,281
310,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,2.31uM (Aβ1-42),fresh,282
311,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,11.55uM (Aβ1-42),fresh,283
312,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,23.1uM (Aβ1-42),fresh,284
313,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,0.231uM (Aβ1-42),aged,285
314,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,2.31uM (Aβ1-42),aged,286
315,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,11.55uM (Aβ1-42),aged,287
316,87,Fig 5,MTT reduction (% vs untreated cells),untreated cells,23.1uM (Aβ1-42),aged,288
317,88,Fig 3,cell viability (%),control,1uM (Aβ1-42),,289
318,88,Fig 3,cell viability (%),control,5uM (Aβ1-42),,290
319,88,Fig 3,cell viability (%),control,10uM (Aβ1-42),,291
320,88,Fig 3,cell viability (%),control,20uM (Aβ1-42),,292
321,88,Fig 3,cell viability (%),control,50uM (Aβ1-42),,293
322,89,Fig 6,Cell viability,control,40uM (Aβ1-42),,294
323,89,Fig S2,Cell viability,control,10uM (Aβ1-42),,295
324,89,Fig S2,Cell viability,control,20uM (Aβ1-42),,296
325,89,Fig S2,Cell viability,control,30uM (Aβ1-42),,297
326,89,Fig S2,Cell viability,control,40uM (Aβ1-42),,298
327,89,Fig S2,Cell viability,control,50uM (Aβ1-42),,299
328,90,Fig 2b,MTT viability (%),untreated cells,1uM mAβ1-42,"24h
The cell viability (%) was expressed as the percentage relative to the control cells (untreated cells)",300
329,90,Fig 2b,MTT viability (%),untreated cells,1uM aAβ1-42,"24h
",301
330,90,Fig 2b,MTT viability (%),untreated cells,1uM mAβ1-42,48h,302
331,90,Fig 2b,MTT viability (%),untreated cells,1uM aAβ1-42,48h,303
332,90,Fig 2b,MTT viability (%),untreated cells,1uM mAβ1-42,72h,304
333,90,Fig 2b,MTT viability (%),untreated cells,1uM aAβ1-42,72h,305
334,91,"Fig 4a
",% SH-SY5Y cells viability,untreated cells,5uM Aβ1-42,,306
335,91,"Fig 4a
",% SH-SY5Y cells viability,untreated cells,10uM Aβ1-42,,307
336,91,"Fig 4a
",% SH-SY5Y cells viability,untreated cells,15uM Aβ1-42,,308
337,91,"Fig 4a
",% SH-SY5Y cells viability,untreated cells,20uM Aβ1-42,,309
338,91,"Fig 4a
",% SH-SY5Y cells viability,untreated cells,25uM Aβ1-42,,310
339,91,"Fig 4a
",% SH-SY5Y cells viability,untreated cells,30uM Aβ1-42,,311
340,91,"Fig 4a
",% SH-SY5Y cells viability,untreated cells,35uM Aβ1-42,,312
341,91,"Fig 4a
",% SH-SY5Y cells viability,untreated cells,40uM Aβ1-42,,313
342,91,Fig 4b,% SH-SY5Y cells viability,untreated cells,25uM Aβ1-42,,314
343,91,Fig 4c,% SH-SY5Y cells viability,untreated cells,25uM Aβ1-42,,315
344,91,Fig 4d,% SH-SY5Y cells viability,untreated cells,25uM Aβ1-42,,316
345,92,Fig 2b,Cells viability (% of vehicle),untreated cells,5uM Aβ1-42,,317
346,92,Fig 2b,Cells viability (% of vehicle),untreated cells,10uM Aβ1-42,,318
347,92,Fig 2b,Cells viability (% of vehicle),untreated cells,20uM Aβ1-42,,319
348,92,Fig 2b,Cells viability (% of vehicle),untreated cells,30uM Aβ1-42,,320
349,92,Fig 2b,Cells viability (% of vehicle),untreated cells,20uM Aβ1-42,,321
350,93,Fig 2,% of control,untreated cells,0.6uM Aβ1-42,oligomeric ,322
351,93,Fig 2,% of control,untreated cells,1.2uM Aβ1-42,oligomeric ,323
352,93,Fig 2,% of control,untreated cells,2.5uM Aβ1-42,oligomeric ,324
353,93,Fig 2,% of control,untreated cells,5uM Aβ1-42,oligomeric ,325
354,93,Fig 2,% of control,untreated cells,0.6uM Aβ1-42,fibrillar,326
355,93,Fig 2,% of control,untreated cells,1.2uM Aβ1-42,fibrillar,330
356,93,Fig 2,% of control,untreated cells,2.5uM Aβ1-42,fibrillar,327
357,93,Fig 2,% of control,untreated cells,5uM Aβ1-42,fibrillar,328
358,94,Fig 1a,Cell viability,untreated cells,25 μM Aβ1-42,,329
359,95,Fig 3a,Cell viability (%),untreated cells,1 μM Aβ1–42,,331
360,96,Fig 6a,Cell viability (%),untreated cells,10 uM Aβ1–42,,332
361,97,Fig 8,Neuronal viability (% vs control),control,10 uM  OAβ1–42,,333
362,98,Fig 7,Cell viability (%),control,Aβ,,334
363,99,Fig 6,Relative cell viability (%),control cells,Aβ1-40,,335
364,99,Fig 7,Relative cell viability (%),control cells,Aβ1-40,,336
365,100,Fig 3b,% of survival,control,1 μM Aβ,,337
366,101,Fig 5,Cell viability (%),control,Aβ42 alone,,338
367,101,Fig 6,Cell viability (%),control,Aβ42,,339
368,102,"Fig 4a
",Cell viability as a fraction of control growth,control,Aβ42 alone,,340
369,102,Fig 4b,Cell viability as a fraction of control growth,control,Aβ42 alone,,341
372,104,Fig 6,MTT reduction ability (relative to control),control,Aβ,,342
373,105,Fig 3e,Relative cell viability (%),control,Aβ,,343
374,106,"Fig 2
",MTT reduction (% of control),no Aβ,Aβ42,,344
375,106,Fig 8a,MTT reduction (% of control),no Aβ,Aβ oligomers,,345
376,107,"Fig 1
","Cell viability, % Control",control,Aβ,,346
377,107,Fig 2b,"Cell viability, % Control",control,Aβ,,347
378,108,Fig 5a,SHSY5Y % cell viability (% of negative control),C-,CAβ,,348
379,109,Fig 6,Cell viability (%),control,Aβ,,349
380,110,Fig 2e,Survival (%),Ctrl,Aβ,,350
381,111,"Fig 7
",Cell viability (% of control),Buffer (control),soluble Aβ42,,351
382,111,"Fig 7
",Cell viability (% of control),Buffer (control),Aβ42 fibril,,352
383,112,Fig 4,MTT reduction (% of control),Cells,Aβ,,353
384,113,Fig 1a,% Viability,0 Aß 0.3 DMSO ,1 Aß 0.3 DMSO,,354
385,113,Fig 1a,% Viability,0 Aß 0.3 DMSO,5 Aß 0.3 DMSO,,355
386,113,Fig 1a,% Viability,0 Aß 0.3 DMSO ,10 Aß 0.3 DMSO,,356
387,113,Fig 1a,% Viability,0 Aß 0.3 DMSO , 20 Aß 0.3 DMSO,,357
388,113,Fig 1a,% Viability,0 Aß 0.3 DMSO ,40 Aß 0.3 DMSO,,358
389,113,Fig 1b,% Viability,0 Aß 0 curcumin 0.3 DMSO ,20 Aß 0 curcumin 0.3 DMSO,,359
390,114,Fig 4,Cell viability (% of control),Control,Aβ1-42,,360